Pharmacotherapy of agitation and psychotic symptoms in Alzheimer’s disease

References

• Austen B, Manca M. Proteins on the brain. Chem. BE 36, 28–31 (2000).
   Google Scholar
• Munoz DG, Feldman H. Causes of Alzheimer's disease. CM4J162, 65–72 (2000).
   Google Scholar
• Clippingdale AB, Wade JD, Barrow CJ. The amyloid-beta peptide and its role in Alzheimer's disease. J. Pept. Sri. 7, 227–249 (2001).
   Google Scholar
• •This outstanding review article discusses thepathyphysiology of AO production, aggregation and neurotoxicity, synthesis and purification of AD peptides, techniques for structural analysis of AD aggregates and AD-based therapeutic sirategies.
   Google Scholar
• Teplow DB. Structural and kinetic features of amyloid Alzheimer's disease and related disorders — protein fibrillogenesis. Amyloict Int. Exp. Clin. Invest. 5, 121–142 (1998).
   PubMed Web of Science ®Google Scholar
• Boss MA. Diagnostic approaches to Alzheimer's disease. Biochim. Biophys. Acta. 1502, 188–200 (2000).
   PubMedGoogle Scholar
• Ernst RL, Hay JVV The US economic and social costs of Alzheimer's disease revisited. Am.Public Health 84, 1261–1264 (1994).
   PubMed Web of Science ®Google Scholar
• Lutz W Sanderson W, Scherbov S. The end of world population growth. Nature 412, 543–545 (2001).
   PubMedGoogle Scholar
• Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. BE j fiychtry157, 72–76 (1990).
   Google Scholar
• Allen NHP, Bums A. The noncognitive features of dementia. Rev Gun. Gerontology 5, 57–75 (1995).
   Google Scholar
• Folstein ME, Bylsma FVV. Noncognitive symptoms of Alzheimer's disease. In: Alzheimer disease (2nd ed). Terry RD, Katzman R, Bick KL, Sisodia SS (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA, 25–37 (1999).
   Google Scholar
• Bathgate D, Snowden JS, Varma A, Blackshaw A, Neary D. Behaviour in frontotemporal dementia, Alzheimer's disease and vascular dementia. Acta Nemo'. Land. 103(6), 367–378 (2001).
   Google Scholar
• Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception. BE j Psychiatry 157, 76–81 (1990).
   Google Scholar
• Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour. BE j Psychiatry 157, 86–94 (1990).
   Google Scholar
• Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am j Psychiatry 157(5), 708–714 (2000).
   PubMed Web of Science ®Google Scholar
• Tariot PN. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry 57\(Suppl. 14), 21–29 (1996).
   Google Scholar
• Finkel SL Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers and caregivers. Clin. PTchiatry62\(Suppl. 21), 3–6 (2001).
   Google Scholar
• Feldman H, Gauthier S, Hecker J et al A 24-week randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology57, 613–620 (2001).
   PubMed Web of Science ®Google Scholar
• •First RCT in which donepezil showed significant benefits on the Clinician's Interview-Based Impression of Change with Caregiver Input in moderate-to-severe AD patients, suggesting that cholinesterase inhibitors as a class may offer a more rational treatment than antipsychotic drugs for behavioral disorders associated with AD.
   Google Scholar
• Narayan M, Nelson JC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. j Clin. PTchiatry58(8), 351–354 (1997).
   Google Scholar
• Alexopoulos GS, Silver JM, Kahn DA et al. The expert consensus guideline series: treatment of agitation in older persons with dementia. Postgracl Merl Special Report, April, 1–88 (1998).
   Google Scholar
• •Expert consensus panel pointing at valproate as first-line treatment for agitation in dementia.
   Google Scholar
• Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J: Arn. Ceriatc Soc. 38(5), 553–563 (1990).
   Google Scholar
• ••This meta-analysis provides a goodoverview of most studies performed with typical antipsychotics on AD patients with agitation and/or psychosis prior to 1989.
   Google Scholar
• Lanctot KL, Best TS, Mittmann N et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J: Clin. fiychiatry59(10), 550–563 (1998).
   Google Scholar
• •• This meta-analysis provides a good overview of most controlled studies performed with typical antipsychotics on AD patients with agitation and/or psychosis prior to 1995.
   Google Scholar
• Devanand DP, Marder K, Michaels KS et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Arn. j Psychiatry 155(11), 1512–1520 (1998).
   PubMedGoogle Scholar
• •This RCT examines the dose—effect relationship of haloperidol in AD patients with agitation and/or psychosis.
   Google Scholar
• Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine and placebo for agitation in Alzheimer's disease. J: Neuropsychiatry Clin. Neurosci. 9(4), 591–593 (1997).
   Google Scholar
• Sultzer DL, Gray IKE Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Arn. j Ceriatc PTchiatry5 (1), 60–69 (1997).
   PubMed Web of Science ®Google Scholar
• Teri L, Logsdon RG, Peskind E et al. Alzheimer's disease Co-operative Study. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 55 (9), 1271–1278 (2000) .
   PubMed Web of Science ®Google Scholar
• Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst. Rev. 2, CD002852 (2002).
   Google Scholar
• ••This meta-analysis provides a goodoverview of all controlled studies performed with haloperidol on AD patients with agitation.
   Google Scholar
• Allain H, Dautzenberg PH, Maurer K, Schuck S, Bonhomme D, Gerard D. Double-blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Rychophatmacology (Berl.). 148(4), 361–366 (2000).
   Google Scholar
• •This RCT compares the efficacy of tiapride versus haloperidol and placebo in agitated and aggressive dementia patients.
   Google Scholar
• Gutzmann H, Kuhl IQ, Kanowski S, Khan- Boluki J. Measuring the efficacy of psychopharmacological treatment of psychomotoric restlessness in dementia: clinical evaluation of tiapride. Pharmacopsychiatry30(1), 6–11 (1997).
   PubMedGoogle Scholar
• Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J: Clin. Psychiatry60(2), 107–115 (1999).
   Google Scholar
• •• This RCT examines the dose—effect relationship of risperidone for agitation and psychosis in patients with the most common types of dementia (AD, vascular or mixed).
   Google Scholar
• De Deyn PP, Rabheru K, Rasmussen A et al A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology 53(5), 946–955 (1999).
   PubMed Web of Science ®Google Scholar
• ••This RCT compares the efficacy of risperidone versus haloperidol and placebo for agitation and psychosis in patients with the most common types of dementia (AD, vascular or mixed).
   Google Scholar
• Street JS, Clark WS, Gannon KS et al Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. PTchiatry57(10), 968–976 (2000).
   Google Scholar
• ••This RCT examines the dose—effectrelationship of olanzapine in AD patients with agitation and/or psychosis.
   Google Scholar
• Clark WS, Street JS, Feldman PD, Breier A. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. Clin. PTchiatry 62 (1), 34–40 (2001) .
   PubMedGoogle Scholar
• McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. I Clin. PTchiatry60(5), 292–298 (1999).
   Google Scholar
• Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long-Term use of quetiapine in elderly patients with psychotic disorders. Clin. Ther. 22(9), 1068–1084 (2000).
   Google Scholar
• Meltzer CC, Smith G, DeKosky ST et al Serotonin in aging, late-life depression and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 18 (6), 407–430 (1998).
   PubMed Web of Science ®Google Scholar
• •Review article discussing relationships between serotonergic neurotransmission and AD, including implications for neuroimaging studies.
   Google Scholar
• Lanctot KL, Herrmann N, Mazzotta P Role of serotonin in the behavioral and psychological symptoms of dementia. Neuropsychiatry Clin. Neurosci. 13(1), 5–21 (2001).
   Google Scholar
• •Review article discussing relationships between serotonergic neurotransmission and behavioral and psychological symptoms in AD, including implications for neuroimaging studies.
   Google Scholar
• Coccaro EE Central serotonin and impulsive aggression. BE j Psychiatry 155(8), 52–62 (1989).
   Google Scholar
• Pollock BG, Mulsant BH, Rosen J et al. Comparison of citalopram, perphenazine and placebo for the acute treatment of
   Google Scholar
• •• psychosis and behavioral disturbances in hospitalized, demented patients. Am. J. Rychiatry159(3), 460–465 (2002).
   Google Scholar
• ••This RCT, which attempted to rule outthe potentially confounding effect of major depressive disorder by selecting nondepressed dementia patients, showed that the efficacy of citalopram on both psychotic symptoms and behavioral disturbances was equal or superior to that of perphenazine and superior to that of placebo.
   Google Scholar
• Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. BE J. Psychiatry 157,894–901 (1990).
   Google Scholar
• ••This was the first RCT that showed thatcitalopram was effective for agitation in AD patients. However, a potentially confounding effect of concurrent major depressive disorder could not be ruled out.
   Google Scholar
• Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. J. Neuropsychiatry Gun. Neurosci. 8(3), 338–340 (1996).
   Google Scholar
• Knutson B, Wolkowitz OM, Cole SW et al Selective alteration of personality and social behavior by serotonergic intervention. Am. PTchMtry 155 (3), 373–379 (1998) .
   PubMed Web of Science ®Google Scholar
• Ekselius L, von Knorring L. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. Int. Gun. fiychopharmacol 13(5), 205–211 (1998).
   Google Scholar
• Verkes RJ, Van der Mast RC, Hengeveld MW Tuyl JP, Zwinderman AH, Van Kempen GM. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am. J. Psychiatry 155 (4), 543–547 (1998).
   Google Scholar
• Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J. Gun. fiychiatry55(4), 137–141 (1994).
   Google Scholar
• Coccaro EF, Astill JL, Herbert JL, Schut AG. Ruoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. J. Gun. Psychopharmacol 10(5), 373–375 (1990).
   Google Scholar
• Vartiainen H, Tiihonen J, Putkonen A et al. Citalopram, a selective serotonin re-uptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychian: Scand. 91 (5), 348–351 (1995).
   Google Scholar
• Pettinate HM, Oslin D, Decker K. Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. CNS Spectmms5, 33–46 (2000).
   Google Scholar
• Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry 57,553–559 (2000).
   Google Scholar
• Seeman P, Tallerico T Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. PTchiatry 156(6), 876–884 (1999).
   Google Scholar
• Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. I Pharmacol Exp. Ther 302(1), 381–389 (2002).
   Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur Pharmacol 441(3), 137–140 (2002).
   Google Scholar
• Mamo DC, Pollock BG, Mulsant B et al Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. Am.j Cerian: PTchiatry 10 (2), 199–205 (2002).
   Google Scholar
• Serpell LC. Alzheimer's amyloid fibrils: structure and assembly. Biochim. Biophys. Acta 1502,16–30 (2000).
   PubMed Web of Science ®Google Scholar
• Roher AE, Baudry J, Chaney MO, Kuo YM, Stine WB, Emmerling MR. Oligomerization and fibril asssembly of the amyloid-beta protein. Biochim. Biophys. Acta 1502,31–43 (2000).
   PubMed Web of Science ®Google Scholar
• Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24,219–224 (2001).
   Google Scholar
• •First article showing evidence that not AP plaques, but small AP oligomers may be associated with the neurotoxicity in AD.
   Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (5580), 353–356 (2002).
   PubMed Web of Science ®Google Scholar
• ••This excellent compact review articlediscusses evidence for and against the AD amyloid hypothesis and AP-based therapeutic strategies.
   Google Scholar
• Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim. Biophys. Acta 1502,76–84 (2000).
   PubMed Web of Science ®Google Scholar
• •Interesting article discussing various techniques used to characterize AD polymerization inhibitors.
   Google Scholar
• Emilien G, Beyreuther K, Masters CL, Maloteaux JM. Prospects for pharmacological intervention in Alzheimer's disease. Arch. Neural. 57(4), 454–459 (2000).
   PubMedGoogle Scholar
• •Review article discussing various pharmacological treatment strategies for AD, such as cholinesterase inhibitors, nicotinic cholinergic strategies, NMDA antagonists, neuroprotective agents, neurotrophic growth factors, agents decreasing the cellular reaction to neurodegeneration, antioxidants and AP reducing agents.
   Google Scholar
• Nordberg A. Neuroprotective mechanisms as treatment strategy in Alzheimer's disease. Gun: Med. Chem. - Central Nervous System Agents 1,239–246 (2001).
   Google Scholar
• •Review article discussing various pharmacological treatment strategies for AD, such as neurotrophic growth factors, anti-inflammatory medications, antioxidants, estrogens, cholinesterase inhibitors, nicotinic cholinergic agonists and antiA13 amyloid substances.
   Google Scholar
• Cutler NR, Sramek JJ. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Prog: Neuropsychophatmacol Biol. fiychMtry25, 27–57 (2001).
   Google Scholar
• •Review article discussing various pharmacological treatment strategies for AD, such as cholinesterase inhibitors, monoamine oxidase inhibitors, selegiline, anti-inflammatory agents, antioxidants, vitamins E and C, estrogen, agents limiting tau hyperphosphorylation, I and y secretase inhibitors and AD antibodies.
   Google Scholar
• Vassar R, Bennett BD, Babu-Khan S et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286,735–741 (1999).
   PubMed Web of Science ®Google Scholar
• Agdeppa E, Kepe V, Satyamurthy N, Small GW, Cole GM, Barrio JR. The in vivo molecular imaging probe [F-181FDDNP demonstrates NSAID binding to A13 senile plaques in Alzheimer's disease. Neurobid Aging-23(1S), S422 (2002).
   Google Scholar
• Koldamova RP Lefterov IM, Lefterova MI, Lazo JS. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 40, 3553–3560 (2001).
   PubMedGoogle Scholar
• Shoghi-Jadid K, Small GW, Agdeppa ED et al Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am.j Ceriatr Bychiatry10, 24–35 (2002).
   PubMed Web of Science ®Google Scholar
• ••First article reporting imaging in vivo ofAD plaques and neurofibrillary tangles in AD patients using [1811FDDNP PET.
   Google Scholar
• Okamura N, Suemoto T, Suzuki M et al New imaging probes for in vivo labeling of amyloid plaques and neurofibrillary tangles. Neurobiol Aging23(1S), S352 (2002).
   Google Scholar
• Zhuang ZP, Kung MP, Hou C et al Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. Med. Chem. 44,1905–1914 (2001).
   Google Scholar
• Zhuang ZP, Kung MP, Hou C et al IBOX(2-(4' -dimethylaminophenyl) -6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nucl. Med. Biol. 28,887-894 (2001).
   Google Scholar
• Mathis CA, Bacskai BJ, Kajdasz ST et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 12(3), 295–298 (2002).
   Google Scholar
• Engler H, Blomqvist G, Bergstrom M et al. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol Aging: 23(1S), S429 (2002).
   Google Scholar
• •• First abstract reporting imaging in vivo of AD plaques in AD patients using [11q6-0H-BTA-1 PET.
   Google Scholar
• Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C, Plossl K. Novel stilbenes as probes for amyloid plaques. jAm Chem. Soc. 123(50), 12740–12741 (2001).
   Google Scholar